New hope for kids with stubborn kawasaki disease: experimental drug tested

NCT ID NCT01596335

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated Jun 07, 2026 · Updated 19 times

Summary

This study tested a drug called TA-650 in 31 children with Kawasaki disease whose fever did not go away after standard IVIG treatment. The goal was to see if TA-650 could reduce fever and prevent heart artery damage better than a control treatment. The trial is complete, and results focus on fever control within 48 hours and long-term heart health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KAWASAKI DISEASE REFRACTORY TO INITIAL THERAPY WITH INTRAVENOUS IMMUNOGLOBULIN are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Investigational site

Chugoku, Japan
Investigational site

Chūbu, Japan
Investigational site

Hokkaido, Japan
Investigational site

Kanto, Japan
Investigational site

Kyushu, Japan
Investigational site

Shinetu, Japan
Investigational site

Tōhoku, Japan
Investigational site

Tōkai, Japan

Conditions

The condition(s) this trial relates to.

Kawasaki disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KAWASAKI DISEASE REFRACTORY TO INITIAL THERAPY WITH INTRAVENOUS IMMUNOGLOBULIN